3,4-dihydropyrrolo[1,2-A]pyrazine-2,8(1H)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof for diseases involving casein kinase 1 epsilon and/or casein kinase 1 delta

US9233965B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Sylvain COTE-DES-COMBES · Ballancourt-sur-Essonne, FR
• Jacques Froissant · Châteaudun, FR
• Jean-Francois Gibert · Paris, FR
• Frank Marguet · Verrières-le-Buisson, FR
• Christophe Pacaud · Cachan, FR
• Frederic Puech · Rueil-Malmaison, FR
• Antoine Ravet · Paris, FR

Key dates

• Filing date: Jul 23, 2014
• Grant date: Jan 12, 2016
• Expiry date: Jul 23, 2034

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds corresponding to the general formula (I)wherein R2 represents a group C1-10-alkyl, C3-10-cycloalkyl, C3-7-cycloalkyl-C1-6-alkyl, C1-6-alkyl-C3-7-cycloalkyl, C3-7-cycloalkyl-C3-7-cycloalkyl, C1-6-alkylthio-C-1-10-alkyl, C1-6-alkoxy-C1-10-alkyl, hydroxy-C1-10-alkyl, hydroxy-C1-6-alkyl-C3-7-cycloalkyl-C1-6-alkyl, hydroxy-C3-10-cycloalkyl, C1-10-fluoroalkyl or C3-10-fluorocycloalkyl; an optionally substituted heterocyclic group; a group C1-10-alkyl substituted with an optionally substituted heterocyclic group; X6 represents a group chosen from hydrogen, fluorine, chlorine and bromine atoms or a group C1-6-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-6-alkyl, C1-6-fluoroalkyl or cyano; and R7 represents an aryl group such as phenyl or naphthyl, optionally substituted with one or more substituents,in the form of the base or of an acid-addition salt, and the therapeutic use thereof.